Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Giovanni Brandi

Showing results (21-30 of 246) with videos related to

Pageof 25
Sort By:
The Lancet. Oncology|July 1, 2021
Second-line FOLFOX chemotherapy for advanced biliary tract cancerGiovanni Brandi, Giorgio Frega, Alessandro Rizzo
Journal of the National Cancer Institute|July 22, 2011
Re: Effect of simvastatin on cetuximab resistance in human colorectal cancer with KRAS mutationsGiovanni Brandi, Guido Biasco, Simona Tavolari
Gastroenterology|November 5, 2022
Have We Found the "Holy Grail" That May Predict Response to Immunotherapy in Hepatocellular Carcinoma?Giovanni Brandi, Francesco Tovoli, Simona Tavolari
Gastroenterology|August 28, 2012
Genomic and genetic characterization of cholangiocarcinoma identifies therapeutics targets for tyrosine kinase inhibitorsGiovanni Brandi, Simona Tavolari, Guido Biasco
Future Oncology (London, England)|January 29, 2021
Immune-based combinations for advanced hepatocellular carcinoma: shaping the direction of first-line therapyAlessandro Rizzo, Angela Dalia Ricci, Giovanni Brandi
Expert Opinion on Investigational Drugs|March 1, 2021
Durvalumab: an investigational anti-PD-L1 antibody for the treatment of biliary tract cancerAlessandro Rizzo, Angela Dalia Ricci, Giovanni Brandi
Cancer Treatment and Research Communications|February 21, 2021
Pemigatinib: Hot topics behind the first approval of a targeted therapy in cholangiocarcinomaAlessandro Rizzo, Angela Dalia Ricci, Giovanni Brandi
Journal of Personalized Medicine|December 29, 2022
Trans-Arterial Chemoembolization Plus Systemic Treatments for Hepatocellular Carcinoma: An UpdateAlessandro Rizzo, Angela Dalia Ricci, Giovanni Brandi
The Oncologist|July 28, 2020
Regarding "HER2 Overexpression as a Poor Prognostic Determinant in Resected Biliary Tract Cancer"Alessandro Rizzo, Angela Dalia Ricci, Giovanni Brandi
Future Oncology (London, England)|August 11, 2020
Systemic adjuvant treatment in hepatocellular carcinoma: tempted to do something rather than nothingAlessandro Rizzo, Angela Dalia Ricci, Giovanni Brandi
Pageof 25

Showing results (21-30 of 246) with videos related to

Sort By:
Pageof 25
The Lancet. Oncology|July 1, 2021
Second-line FOLFOX chemotherapy for advanced biliary tract cancerGiovanni Brandi, Giorgio Frega, Alessandro Rizzo
Journal of the National Cancer Institute|July 22, 2011
Re: Effect of simvastatin on cetuximab resistance in human colorectal cancer with KRAS mutationsGiovanni Brandi, Guido Biasco, Simona Tavolari
Gastroenterology|November 5, 2022
Have We Found the "Holy Grail" That May Predict Response to Immunotherapy in Hepatocellular Carcinoma?Giovanni Brandi, Francesco Tovoli, Simona Tavolari
Gastroenterology|August 28, 2012
Genomic and genetic characterization of cholangiocarcinoma identifies therapeutics targets for tyrosine kinase inhibitorsGiovanni Brandi, Simona Tavolari, Guido Biasco
Future Oncology (London, England)|January 29, 2021
Immune-based combinations for advanced hepatocellular carcinoma: shaping the direction of first-line therapyAlessandro Rizzo, Angela Dalia Ricci, Giovanni Brandi
Expert Opinion on Investigational Drugs|March 1, 2021
Durvalumab: an investigational anti-PD-L1 antibody for the treatment of biliary tract cancerAlessandro Rizzo, Angela Dalia Ricci, Giovanni Brandi
Cancer Treatment and Research Communications|February 21, 2021
Pemigatinib: Hot topics behind the first approval of a targeted therapy in cholangiocarcinomaAlessandro Rizzo, Angela Dalia Ricci, Giovanni Brandi
Journal of Personalized Medicine|December 29, 2022
Trans-Arterial Chemoembolization Plus Systemic Treatments for Hepatocellular Carcinoma: An UpdateAlessandro Rizzo, Angela Dalia Ricci, Giovanni Brandi
The Oncologist|July 28, 2020
Regarding "HER2 Overexpression as a Poor Prognostic Determinant in Resected Biliary Tract Cancer"Alessandro Rizzo, Angela Dalia Ricci, Giovanni Brandi
Future Oncology (London, England)|August 11, 2020
Systemic adjuvant treatment in hepatocellular carcinoma: tempted to do something rather than nothingAlessandro Rizzo, Angela Dalia Ricci, Giovanni Brandi
Pageof 25